SpeeDx's diagnostic test can identify both M. genitalium and mutations in the 23S rRNA gene of the bacteria that exhibit resistance to azithromycin, a commonly prescribed macrolide-based antibiotic.
UgenTec's solution FastFinder solution will automatically interpret the results, as well as offers automation for incorporation to multiple laboratory information systems.
SpeeDx is also planning to expand the interpretation module to its other products, including PlexPCR HSV-1&2, VZV, Syphilis and PlexPCR RespiVirus products.
SpeeDx provides multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics.
Its CE-IVD multiplex qPCR kits will enable to detect infectious disease pathogens and antimicrobial resistance markers.
UgenTec provides artificially intelligent platform to the molecular diagnostic market. The platform will allow scientists to interpret PCR data.
SpeeDx CEO Colin Denver said: “Combining our high performance and reliable assays with UgenTec's software is unique in today's diagnostic landscape.
"We can now provide a validated solution for multiple qPCR instruments to help speed the delivery of results during routine diagnostic use."
UgenTec CEO Wouter Uten said: "UgenTec is looking forward to providing the customers of SpeeDx with an artificially intelligent assistant. It will provide them with powerful machine learning algorithms.”
